{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhou X"],"funding":["National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["e2407043"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11538650"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(41)"],"pubmed_abstract":["Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS-responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self-assembled into nanoparticles (uhOLN-NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN-NPs to form nanoparticles with hypoxic and ROS responses ("],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["Self-Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments."],"pmcid":["PMC11538650"],"funding_grant_id":["82171058","2021YFA1101200","2021YFA1101202","U23A20435","82271091"],"pubmed_authors":["Ji D","Xia X","Liang G","Rong R","Xiao H","Xu C","Zhou X","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Self-Assembly Hypoxic and ROS Dual Response Nano Prodrug as a New Therapeutic Approach for Glaucoma Treatments.","description":"Glaucoma is an irreversible blinding eye disease characterized by retinal ganglion cell (RGC) death.Previous studies have demonstrated that protecting mitochondria and activating the CaMKII/CREB signaling pathway can effectively protect RGC and axon. However, currently treatments are often unsatisfactory, and the pathogenesis of glaucoma requires further elucidation. In this study, a ROS-responsive dual drug conjugate (OLN monomer) is first designed that simultaneously bonds nicotinamide and oleic acid. The conjugate self-assembled into nanoparticles (uhOLN-NPs) through the aggregation of multiple micelles and possesses ROS scavenging capability. Then, a polymer with a hypoxic response function is designed, which encapsulates uhOLN-NPs to form nanoparticles with hypoxic and ROS responses (","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2025-04-04T03:04:43.864Z","creation":"2025-04-04T03:04:43.864Z"},"accession":"S-EPMC11538650","cross_references":{"pubmed":["39229928"],"doi":["10.1002/advs.202407043"]}}